PD-1 blockade in tumors with mismatch repair deficiency.

By J. Uram, Hao Wang, Bjarne R. Bartlett, H. Kemberling, A. Eyring, A. Skora, N. Azad, D. Laheru, R. Donehower, Brandon S. Luber and 9 more. Journal of Clinical Oncology, 2015

4,126 citations recorded by the source corpus.

Subfields: Epidemiology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/78484c57a642593ba7c02a165c1e95b246b11343

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Oncology

In Pathology and Forensic Medicine

Citations in the corpus

Landscape of Microsatellite Instability Across 39 Cancer Types (2017, positive): “durable responses and a statistically significant improvement in overall survival.(12)”
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018, background): “This was particularly noted in anti-CTLA-4-treated melanoma patients whose tumors displayed neo-antigens (87) and similarly in anti-PD-1-treated patients with colorectal cancers or non-small cell lung cancers that were mismatch-repair deficient or had high mutation rates, respectively (78, 86).”
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma (2016, background): “MMR-deficient tumors were recently shown susceptibility to checkpoint blockade immunotherapy (7).”
Artificial intelligence in histopathology: enhancing cancer research and clinical oncology (2022, background): “An intermediate step is to predict established markers of treatment response, such as microsatellite instability (MSI) in colorectal 57–61 , gastric 62 or endometrial cancer 63 , which renders these tumors susceptible to immunotherapy with immune check-point inhibitors 64 .”
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma (2015, positive): “This result confirms previous findings for ipilimumab in melanoma (13) and is consistent with observations regarding response to other immune checkpoint inhibitors in cancer (23, 24).”
The microenvironmental landscape of brain tumors (2017, result): “Similar results have also been reported in metastatic cancers harboring mismatch repair deficiencies and high frequency of somatic mutations (Le et al., 2015).”
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab (2017, background): “The underlying genomic features of a tumor can contribute to its response to checkpoint blockade, and increased tumor mutation load associates with survival benefits from both anti-CTLA-4 and anti-PD-1 therapy in multiple malignancies (Hugo et al., 2016; Le et al., 2015; Rizvi et al., 2015; Rosenber”
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. (2016, background): “Beyond melanoma and NSCLC, ICBs are showing promising responses across many different cancer subtypes including small-cell lung cancer [15% objective response rate (ORR)] [1], renal cell carcinoma (25% ORR) [2], urothelial cancer (25% ORR) [3], head and neck squamous cell carcinoma (12%–25% ORR) [4,”
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials (2017, background): “This prognostic difference was independent of the first-line regimen, suggesting that there is a significant unmet clinical need for developing new treatment strategies for patients with rightsided mCRC.(22) Furthermore, inbothCRYSTALandFIRE-3,FOLFIRIpluscetuximab had higher treatment effects in lef”
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “0 months, respectively, in the cohort with MMR-proficient tumours [84].”
Primary resistance to PD-1 blockade mediated by JAK1/2 mutations (2016, background): “Blocking the programmed death 1 (PD-1) negative immune receptor results in unprecedented rates of long lasting anti-tumor activity in patients with metastatic cancers of different histologies, including melanoma, Hodgkin’s disease, Merkel cell, head and neck, lung, esophageal, gastric, liver, kidney”